The Whitespace Tax: Why Biotechs Lose Time, Money, and Patients Before First-Patient-In

Today’s essay is a reflection on last week’s marathon of meetings with over 20 sites across the US and EU, and the three study-rescue strategy calls with biotech founders I had this week. A ClinOps director at a pharma company with a blue ribbon logo told me, “Zina, the worst thing you can do to an asset with high potential is run a clinical trial.”

Too depressing to even laugh at. So today’s essay is about how to make sure that joke never comes true.

For those working in clinical operations, this is a reminder of the human systems that make or break medical progress. For those outside the industry, it’s a window into why some trials run smoothly and others stall before patients ever get access.

At 4:16 p.m. on an airless August Thursday, Michelle Eubanks; director of Research Program at a major academic research center; opens an email flagged URGENT / CMP COST. The sponsor of a Phase II liver-cancer trial wants to trim $42 from the budgeted price of a Comprehensive Metabolic Panel, the routine blood test that checks kidney and liver function.

The amount is trivial now, but will certainly compound across the assessment schedule. But until the number is agreed, the academic Centre’s lawyers won’t release the clinical-trial agreement for signature. Without that, the site can’t schedule an initiation visit, can’t hit Ready to Enroll, and certainly can’t dose the first patient.

Eubanks sighs and dials the only person authorized to approve the edit, a project manager at a contract research organization two time zones west. Voicemail. Another day slips into what insiders call the white space: the silence between “site selected” and “site activated.”

The Hidden Physics of Delay

Multiply Michelle’s scene by the 4,000+ industry-sponsored trials launched this year and you see the hidden physics of drug development. Press releases blame regulation, biology, or manufacturing. But the people who unlock the clinic door often give a quieter diagnosis: no one with authority picks up the phone.

I’ve lived both sides of the line; at a CRO and at a sponsor. Four years ago, running Phase III breast-cancer studies at AstraZeneca, I learned that the feared Eroom’s Law isn’t an inevitability, it’s an operational culture problem.

Today, at Yendou, a firm that manages and tracks site-sponsor/CRO engagement, we quantify the cost. Trials that began with strong sponsor–site contact during startup reached first-patient-in 29% faster than those without. For a biotech, that’s three to six months of burn-rate savings; often the difference between hitting milestones and missing the next raise.

Every day of White Space costs about $80,000 in salaries, lab services, and leased equipment. Big Pharma can absorb it. A Series A biotech cannot. As Napoleon put it:

How the White-Space Tax Is Baked In

Sponsors make the problem worse by underpricing site labor to signal fiscal discipline to investors. The strategy backfires. Trials launched with budgets sites deemed unrealistic took 39% longer to activate, recruited 29% fewer patients, and ran 30% longer overall.

One principal investigator at a large academic center told me:

The fastest contract on their books? Two weeks, because the sponsor picked up the phone, accepted fair-market rates, and wired a startup payment. The slowest? Nine months of email ping-pong, ending at the exact same budget number, only with more bruises and resentment.

The White-Space Tax thrives in those nine months.

The Timing Problem

Delays aren’t inevitable. Today, I want to talk about protocol amendment delays. Why? Because the question Biotech CEOs ask me most is, “Zina, when should I engage with sites?” My answer: whatever you think is the right time, it’s already too late.

A 2024 BioPharma Excellence analysis found that when sponsors shared draft protocols with sites before feasibility questionnaires, protocol amendment rates fell by half.

Tufts data show 45% of amendments are avoidable, mostly caused by design flaws or unrealistic eligibility criteria that sites could flag early. Each amendment adds an average of four months and up to $535,000 in costs, another form of White-Space Tax, paid in both time and cash.

Critics argue early engagement doesn’t scale. Technology solves part of this: platforms like Yendou can gather structured feedback from dozens of sites across continents without derailing an IND timeline.

But software alone can’t replace narrative. Truth is: Sites work late because they believe in the science not because of a slide deck. You must engage sites early. But even more important, you must engage them right. Why your molecule? like really why?

The Human Cost of the White-Space Tax

The human cost rarely appears in spreadsheets.

Elena, a 48-year-old mother of two with metastatic triple-negative breast cancer, had undergone two lines of therapy and a failed clinical trial attempt when she found a trial that fit. The investigator told her initiation might take two to three months. She asked me if I knew the ClinOps team at the sponsor and could check for her. The sponsor was stalling over an imaging budget overrun. By the time the site opened, her disease had advanced. She moved to palliative care and died that June.

In 2024, I’ve had 3 terminal patients ask me to call a sponsor to find out when a site would open, because their lives depended on it. Sometimes, there were no plans to open the site at all; it was a “rescue site” held in reserve to block competitors, without the site itself knowing. The delay was entirely strategic.

The White-Space Tax is never just an operational inconvenience.

A Modest Proposal for BioTech Founders

If you’re a biotech founder, here’s the checklist I wish I’d had a decade ago:

1. Draft protocol? Call fifty+ sites. Ask investigators AND coordinators to break it. Revise accordingly.
2. Budget? Pay fair-market rates. Wire a startup tranche on signature.
3. Communication plan? Two names and two numbers: one at the sponsor, one at the site, with 24-hour response accountability.
4. Documentation? Record the call in your eTMF. Speed and compliance are not mutually exclusive.
5. Repeat at every amendment.

Do this and you buy time for iteration, for regulatory surprises, for patients whose diseases don’t pause while email threads keep stretching.

The Call

Back to Eubanks. She finally reaches a junior associate at the CRO, who promises to escalate the $42 conflict. She hangs up, updates the tracker, and checks the clock: 4:17 p.m. Another day slips into the white space. Somewhere, a patient waits.

A single phone call won’t fix clinical research. But the absence of one can kill a study and, sometimes, the desperate hope bound to it.